However, the findings of our study should strengthen the body of evidence to suggest targeted screening for NAFLD in individuals with obesity, elevated FPG, elevated ALT and high FRS category. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.